JP2019531259A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531259A5
JP2019531259A5 JP2019502696A JP2019502696A JP2019531259A5 JP 2019531259 A5 JP2019531259 A5 JP 2019531259A5 JP 2019502696 A JP2019502696 A JP 2019502696A JP 2019502696 A JP2019502696 A JP 2019502696A JP 2019531259 A5 JP2019531259 A5 JP 2019531259A5
Authority
JP
Japan
Prior art keywords
seq
sequence
pharmaceutical composition
item
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019502696A
Other languages
English (en)
Japanese (ja)
Other versions
JP7107914B2 (ja
JP2019531259A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/042855 external-priority patent/WO2018017714A1/en
Publication of JP2019531259A publication Critical patent/JP2019531259A/ja
Publication of JP2019531259A5 publication Critical patent/JP2019531259A5/ja
Priority to JP2022075926A priority Critical patent/JP2022101694A/ja
Application granted granted Critical
Publication of JP7107914B2 publication Critical patent/JP7107914B2/ja
Priority to JP2024186570A priority patent/JP2025011323A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019502696A 2016-07-20 2017-07-19 ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体 Active JP7107914B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022075926A JP2022101694A (ja) 2016-07-20 2022-05-02 ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体
JP2024186570A JP2025011323A (ja) 2016-07-20 2024-10-23 ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662364381P 2016-07-20 2016-07-20
US62/364,381 2016-07-20
US201662377072P 2016-08-19 2016-08-19
US62/377,072 2016-08-19
PCT/US2017/042855 WO2018017714A1 (en) 2016-07-20 2017-07-19 HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020120521A Division JP2020180156A (ja) 2016-07-20 2020-07-14 ＶＥ−ＰＴＰ（ＨＰＴＰ−β）を標的化するヒト化モノクローナル抗体
JP2022075926A Division JP2022101694A (ja) 2016-07-20 2022-05-02 ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2019531259A JP2019531259A (ja) 2019-10-31
JP2019531259A5 true JP2019531259A5 (cg-RX-API-DMAC10.html) 2020-08-27
JP7107914B2 JP7107914B2 (ja) 2022-07-27

Family

ID=60988231

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019502696A Active JP7107914B2 (ja) 2016-07-20 2017-07-19 ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体
JP2020120521A Pending JP2020180156A (ja) 2016-07-20 2020-07-14 ＶＥ−ＰＴＰ（ＨＰＴＰ−β）を標的化するヒト化モノクローナル抗体
JP2022075926A Pending JP2022101694A (ja) 2016-07-20 2022-05-02 ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体
JP2024186570A Pending JP2025011323A (ja) 2016-07-20 2024-10-23 ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020120521A Pending JP2020180156A (ja) 2016-07-20 2020-07-14 ＶＥ−ＰＴＰ（ＨＰＴＰ−β）を標的化するヒト化モノクローナル抗体
JP2022075926A Pending JP2022101694A (ja) 2016-07-20 2022-05-02 ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体
JP2024186570A Pending JP2025011323A (ja) 2016-07-20 2024-10-23 ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体

Country Status (13)

Country Link
US (6) US10253094B2 (cg-RX-API-DMAC10.html)
EP (1) EP3487518A4 (cg-RX-API-DMAC10.html)
JP (4) JP7107914B2 (cg-RX-API-DMAC10.html)
KR (1) KR20190031246A (cg-RX-API-DMAC10.html)
CN (1) CN109715189B (cg-RX-API-DMAC10.html)
AU (2) AU2017299581B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019001206A2 (cg-RX-API-DMAC10.html)
CA (1) CA3030298A1 (cg-RX-API-DMAC10.html)
IL (1) IL263936A (cg-RX-API-DMAC10.html)
MX (1) MX2019000727A (cg-RX-API-DMAC10.html)
PH (1) PH12019500145A1 (cg-RX-API-DMAC10.html)
SG (2) SG10201912556VA (cg-RX-API-DMAC10.html)
WO (1) WO2018017714A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
EP3501536B1 (en) * 2011-10-13 2025-12-24 EyePoint Pharmaceuticals, Inc. Treatment of ocular disease
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
SG10201912556VA (en) 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
WO2019246363A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020041361A1 (en) * 2018-08-20 2020-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
EP3856245A4 (en) * 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF
EA202191201A1 (ru) * 2018-12-03 2022-01-26 Эдженсис, Инк. Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения
WO2020219719A1 (en) * 2019-04-24 2020-10-29 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof
CN115003328A (zh) 2019-10-22 2022-09-02 西奈山伊坎医学院 重组神经氨酸酶及其用途
WO2021091791A1 (en) * 2019-11-06 2021-05-14 Northwestern University Inhibition of the ve-ptp phosphatase protects the kidney from ischemia-reperfusion injury

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
NZ514434A (en) 1999-03-26 2003-11-28 Univ California Modulation of vascular permeability by means of TIE2 receptor activators
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
EP1046715A1 (en) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
US20020068066A1 (en) * 1999-08-20 2002-06-06 Wenyuan Shi Method for the treatment and prevention of dental caries
PT1292335E (pt) 2000-06-23 2007-08-13 Bayer Schering Pharma Ag Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii)
CN1318093C (zh) 2001-09-28 2007-05-30 参天制药株式会社 含与聚乙二醇结合的药物的眼组织注射剂
US20050260132A1 (en) 2001-10-17 2005-11-24 Daniel Chin Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
WO2003047611A2 (en) 2001-12-04 2003-06-12 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Ptp10d, tec and edtp involved in triglycerid-metabolism
US20030215899A1 (en) 2002-02-13 2003-11-20 Ceptyr, Inc. Reversible oxidation of protein tyrosine phosphatases
US20040023880A1 (en) 2002-05-03 2004-02-05 Gale Nicholas W. Methods of inducing formation of functional and organized lymphatic vessels
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
CN101163501A (zh) 2005-02-23 2008-04-16 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
CA2622772A1 (en) 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
EP1962903B1 (en) 2005-12-15 2013-03-13 MedImmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
CA2622312A1 (en) 2006-01-30 2007-08-02 (Osi) Eyetech, Inc. Combination therapy for the treatment of neovascular disorders
SG170091A1 (en) 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
JP2010531896A (ja) 2007-06-26 2010-09-30 チルドレンズ メディカル センター コーポレーション 治療的投与のためのＭｅｔＡＰ−２阻害剤ポリマーソーム
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2009154026A1 (ja) 2008-06-20 2009-12-23 国立大学法人岡山大学 石灰化小球に対する抗体及びその用途
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
PT2385763T (pt) 2009-01-12 2018-07-13 Aerpio Therapeutics Inc Métodos para tratar o síndrome de extravasamento vascular
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
WO2010097800A1 (en) 2009-02-26 2010-09-02 Muhammad Abdulrazik Synergistic combination of bioactive compounds for lowering of intraocular pressure
WO2010111180A1 (en) * 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
BRPI1006897A2 (pt) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compostos, composições e métodos de prevenção da metástase de células cancerosas.
CA3040276A1 (en) * 2009-12-02 2011-06-09 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
CA2818215C (en) 2010-10-07 2015-07-21 Aerpio Therapeutics Inc. Compositions and methods for treating ocular edema, neovascularization and related diseases
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
AU2012214146A1 (en) 2011-02-11 2013-08-29 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
EP3501536B1 (en) 2011-10-13 2025-12-24 EyePoint Pharmaceuticals, Inc. Treatment of ocular disease
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
AU2013342275B2 (en) 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP6572201B2 (ja) 2013-03-15 2019-09-04 エアーピオ セラピューティクス インコーポレイテッド 眼疾患を処置するための組成物、製剤、および方法
US20160130321A1 (en) 2013-06-20 2016-05-12 Gabriela Burian Use of a vegf antagonist in treating macular edema
JP2016522249A (ja) 2013-06-20 2016-07-28 ノバルティス アーゲー 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用
JP2016523956A (ja) 2013-07-11 2016-08-12 ノバルティス アーゲー 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用
BR112016000177A2 (pt) 2013-07-11 2017-12-12 Novartis Ag usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
MX377714B (es) 2013-10-18 2025-03-11 Regeneron Pharma Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
CN105026433B (zh) 2014-01-24 2018-10-19 上海恒瑞医药有限公司 VEGF与PDGFRβ双特异性融合蛋白及其用途
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9719135B2 (en) * 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
TN2017000066A1 (en) 2014-09-16 2018-07-04 Ovascience Inc Anti-vasa antibodies, and methods of production and use thereof.
US20160082129A1 (en) 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
US9458211B1 (en) 2015-04-02 2016-10-04 Molecular Partners Ag Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
JP6959912B2 (ja) 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
CN109069638B (zh) 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
SG10201912556VA (en) 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF

Similar Documents

Publication Publication Date Title
JP2022502367A5 (cg-RX-API-DMAC10.html)
AU2025271125A1 (en) Methods for treating or preventing ophthalmological conditions
Avery et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
Kovach et al. Anti‐VEGF treatment strategies for wet AMD
US20210220436A1 (en) Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
JP2014532072A5 (cg-RX-API-DMAC10.html)
IL277215B1 (en) Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
JP2022512920A5 (cg-RX-API-DMAC10.html)
CN120058958A (zh) 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
JP2010528047A5 (cg-RX-API-DMAC10.html)
JP2016536369A5 (cg-RX-API-DMAC10.html)
JP2017535285A5 (cg-RX-API-DMAC10.html)
FI3227675T3 (fi) Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
JP2015528454A5 (cg-RX-API-DMAC10.html)
RU2012131251A (ru) Композиции и способы для лечения связанных с ангиогенезом заболеваний глаз
WO2014062659A4 (en) Methods of treating ocular diseases
Frampton Aflibercept for intravitreal injection: in neovascular age-related macular degeneration
JP2019535651A5 (cg-RX-API-DMAC10.html)
CN103764830A (zh) 含有irs-1抑制剂和vegf抑制剂的组合物
CN108602879A (zh) 用于治疗疾病的抗体-药物协同作用技术
JP7650074B2 (ja) 眼疾患を治療するための組成物及び方法
Zaki et al. Subconjunctival bevacizumab for corneal neovascularization
MX2020007948A (es) Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular.
JP2009538916A5 (cg-RX-API-DMAC10.html)
Esipov et al. Antiangiogenic and antivascular effects of a recombinant tumstatin-derived peptide in a corneal neovascularization model